Efficacy and safety profile of two-dose SARS-CoV-2 vaccines in cancer patients: An observational study in China

Table 1 Demographic and baseline characteristics of the study population in the two groups

	Healthy	Cancer	P value
Number	215	132
Age			< 0.001
mean ± SD	46.2 ± 8.1	58 ± 5.4
Sex			0.12
Male	137 (63.7%)	73 (55.3%)
Female	78 (36.3%)	59 (44.7%)
History of hypertension			0.17
Yes	69 (32.1%)	52 (39.4%)
No	146 (67.9%)	80 (60.6%)
Smoking history			0.06
Yes	50 (23.3%)	43 (32.6%)
No	165 (76.7%)	89 (67.4%)
BMI	27.5 ± 1.5	26.9 ± 1.2	< 0.001
Diabetes mellitus			0.01
Yes	21 (9.8%)	25 (18.9%)
No	194 (90.2%)	107 (81.1%)
Coronary disease			0.22
Yes	15 (7.0%)	5 (3.8%)
No	200 (93.0%)	127 (96.2%)
Respiratory disease			0.19
Yes	11 (5.1%)	3 (2.3%)
No	204 (94.9%)	129 (97.7%)
Type of vaccine			0.69
Sinovac	133 (61.9%)	85 (64.4%)
Beijing biological	49 (22.8%)	25 (18.9%)
Wuhan biological	33 (15.3%)	22 (16.7%)

BMI: Body mass index.